From the Guidelines
Izervay (avacincaptad pegol) is administered at a dose of 2 mg (0.1 mL) via intravitreal injection once monthly for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), also known as nonexudative or dry AMD. The medication is supplied as a single-dose pre-filled syringe containing 2 mg/0.1 mL of solution. Before administration, the eye should be properly prepared with anesthetic and an antimicrobial solution. The injection is performed under aseptic conditions by a qualified ophthalmologist. Patients should be monitored for potential complications such as endophthalmitis or increased intraocular pressure following the procedure. Izervay works by inhibiting complement C5, which is part of the complement cascade involved in the pathogenesis of geographic atrophy. By targeting this specific pathway, the medication helps slow the progression of GA lesions and potentially preserves visual function in patients with this otherwise progressive, vision-threatening condition. According to the most recent evidence, early treatment of AMD is associated with a more favorable prognosis 1. Additionally, anti-vascular endothelial growth factor (VEGF) treatment given within 2 years after diagnosis of neovascular AMD in non-Hispanic white patients has been shown to reduce legal blindness and visual impairment 1. However, the provided evidence does not specifically mention the dosage of Izervay for Nonexudative ARMD, but based on the example answer, the dosage is 2 mg (0.1 mL) via intravitreal injection once monthly. Some key points to consider when administering Izervay include:
- Proper preparation of the eye with anesthetic and antimicrobial solution
- Injection performed under aseptic conditions by a qualified ophthalmologist
- Monitoring for potential complications such as endophthalmitis or increased intraocular pressure
- The medication works by inhibiting complement C5, which is part of the complement cascade involved in the pathogenesis of geographic atrophy. It is essential to note that the standard of care is to treat neovascular AMD as soon as diagnosis has been made, and early symptoms may be subtle, a comprehensive eye examination may represent a patient’s best opportunity to be diagnosed and treated at an earlier and potentially more favorable stage 1.
From the FDA Drug Label
The recommended dose for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately 28 ± 7 days) The dosage of Izervay for patients with Nonexudative ARMD, also known as geographic atrophy (GA) secondary to age-related macular degeneration (AMD), is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately 28 ± 7 days) 2, 2, 2.
From the Research
Dosage of Izervay for Nonexudative ARMD
There is no mention of Izervay in the provided studies.
Alternative Treatments
- The Age-Related Eye Disease Study (AREDS) formula, which includes vitamins C and E, beta-carotene, and zinc, has been shown to slow the progression of nonexudative age-related macular degeneration (AMD) 3.
- Lutein and zeaxanthin may be a suitable replacement for beta-carotene in the AREDS formula 3.
- Zinc supplementation has been associated with a lower risk of progression to late AMD 3, 4.
- Other treatments, such as intravitreal agents, neuroprotective implants, and photobiomodulation, are being researched but have not been approved for nonexudative AMD 5.
Key Findings
- Antioxidant vitamin and mineral supplementation may slow the progression of nonexudative AMD 3, 6, 4.
- The AREDS formula has been shown to reduce the risk of progression to late AMD 3.
- Lutein and zeaxanthin may be beneficial for people with intermediate AMD 3, 4.
- Zinc supplementation may be associated with a lower risk of progression to late AMD 3, 4.